7 minute read
Journal News
New Editor for Molecular Pharmacology
Dr. John Tesmer ASPET’s Publications Committee is pleased to announce that Dr. John Tesmer has been selected to succeed Dr. Kathryn Meier as editor of Molecular Pharmacology. The transition to the new editors is effective January 1, 2023.
Advertisement
Dr. Tesmer, Distinguished Professor of Biological Sciences, Purdue University, has served in various professorial positions at Purdue University, the University of Michigan, and the University of Texas at Austin.
Having most recently served as Deputy Editor on the editorial board of Molecular Pharmacology, he has been very active with ASPET, having served on ASPET’s Molecular Pharmacology Executive Committee, Programming Committee, Awards Committee, Finance Committee, Council, and served as Chair of ASPET’s Molecular Pharmacology Division. In addition, Dr. Tesmer has also worked in various capacities on other editorial boards and positions of peer review and in volunteer service.
As of this writing, he has published 116 research articles and 28 invited reviews. He also holds 7 U.S. patents. He is the recipient of numerous honors and awards, including ASPET’s John J. Abel Award in 2009.
We extend our thanks and say farewell to outgoing editor Dr. Kathryn Meier as she hands over the reins to Dr. Tesmer.
New PharmRev Associate Editors and MolPharm Editorial Board Members
The Publications Committee recently approved the following new Associate Editors for Pharmacological Reviews:
■ Dr. Andrew Baker, University of Edinburgh, UK and Maastricht University, NL ■ Dr. Erin Calipari, Vanderbilt University,
Nashville, TN ■ Prof. Kay Double, University of Sydney,
Australia ■ Prof. Michelle Glass, University of Otago,
Dunedin, New Zealand ■ Dr. Francesca Levi-Schaffer, The Hebrew
University of Jerusalem, Israel ■ Dr. Sara Liin, Linköping University, Sweden ■ Prof. Harald Sitte, Medical University of Vienna,
Austria ■ Dr. Joanne Wang, University of Washington,
Seattle, WA
Dr. Andrew Baker Dr. Erin Calipari
Prof. Kay Double Prof. Michelle Glass
Dr. Francesca LeviSchaffer Dr. Sara Liin
Prof. Harald Sitte Dr. Joanne Wang Dr. Jennifer Cash Dr. Alisa Glukhova Dr. Naoto Hoshi
Dr. Ole Valente Mortensen Dr. Senthil Natesan Dr. John Traynor
The Committee also recently approved the following new Molecular Pharmacology Editorial Board members:
■ Dr. Jennifer Cash, University of California-Davis,
CA ■ Dr. Alisa Glukhova, The Walter and Eliza Hall
Institute of Medical Research and The University of Melbourne, Australia ■ Dr. Naoto Hoshi, University of California, Irvine ■ Dr. Ole Valente Mortensen, Drexel University,
Philadelphia, PA ■ Dr. Senthil Natesan, Washington State
University, Spokane, WA ■ Dr. John Traynor, University of Michigan,
Ann Arbor
The Publications Committee thanks them and all ASPET editorial board members for their service and dedication to the Society’s journals.
A special section on Quantitative Systems Pharmacology (QSP) is being planned for publication in the June 2023 issue of The Journal of Pharmacology and Experimental Therapeutics.
Original research pertaining to QSP will be considered for publication in this special section. QSP has established itself as a challenging and unique discipline that produces mechanistic models of drug action, either action related to therapeutic efficacy and/or those related to drug toxicity. The field is an extension of pharmacodynamics in that relevant protein-protein interaction pathways and networks are represented in the models providing a systems-level view of drug action. Manuscripts describing new and innovative QSP models, as well as computational tools, such as machine learning, to develop and evaluate QSP models, manually or through automatic model learning, and means to incorporate multi-omic data into model building, are especially welcome. Other QSP research topics, such as those related to drug development, including in vitro/in vivo or interspecies model scaling, are also appreciated. Presubmission proposals are welcome and will be evaluated by our guest editors listed below.
Original articles addressing any aspects of the aforementioned topics will be considered. Please send a presubmission inquiry and include in your cover letter your interest in being considered for the special section, the title, abstract, significance statement, and full author information to the Journal of Pharmacology and Experimental Therapeutics in advance of full submission. The guest editors, Dr. James M. Gallo and Dr. Annabelle Ballesta, will review your presubmission inquiry and respond with comments and suggestions, and will assess whether final approval will be granted for a full submission. All submissions to the journal must refer to the journal Instructions to Authors (https://jpet.aspetjournals.org/content/ifora) where specific guidelines on research articles are located.
A special section on Clinical Pharmacology is being planned for publication in the August 2023 issue of The Journal of Pharmacology and Experimental Therapeutics.
The full paper submission deadline is December 2022.
This will be a dedicated forum for original research on various aspects of clinical pharmacology, including but not limited to experimental and regulatory aspects of drug development, Phase I-II studies, therapeutic drug monitoring, pharmacokinetic and/ or efficacy and safety issues in a special population (children, the elderly, multi-morbidity patients), population pharmacokinetics, pharmacogenomics, personalized pharmacotherapies, advanced therapies (gene and cell therapy), and bioinformatics.
Original articles addressing any aspects of the aforementioned topics will be considered; please send a presubmission inquiry and include the title, abstract, significance statement, and full author information to The Journal of Pharmacology and Experimental Therapeutics in advance of full submission. The guest editor, Dr. Giorgio Minotti, will review the presubmission inquiry, respond to the authors with comments, and assess whether final approval will be granted for a full submission. All submissions to the journal must refer to the journal Instructions to Authors (https://jpet.aspetjournals.org/content/ifora) where specific guidelines on research articles are located.
Call for Papers for Special Section on Sphingolipids for Molecular Pharmacology
A special section entitled Therapeutic Implications for Sphingolipids in Health and Disease is expected to be published in the January 2024 issue of Molecular Pharmacology.
We are looking for the following:
■ Original research pertaining to novel inhibitors and drugs targeting sphingolipid metabolism in disease, as well as novel roles for sphingolipids in therapeutic responses; ■ Manuscripts describing efforts in demonstrating the efficacy of novel sphingolipid inhibitors, as well as their emerging functional role as targets to treat human disease; ■ Research papers describing innovative in vitro/ ex vivo/in vivo, bioanalytical, -omics, modeling, and/or clinical research approaches; and ■ Approaches that advance the understanding of the sphingolipids as novel targets or describing their function in therapeutic responses.
Review articles addressing any aspects of the aforementioned topics will be considered, and proposals should be sent to the guest editors, Dr. Ashley Snider or Dr. Chris Clarke, for approval prior to submission. All interested individuals are strongly encouraged to refer to the Molecular Pharmacology Instructions to Authors before submission of articles. The full paper submission deadline is April 2023.
Call for Papers on Protein and Peptide Therapeutics for JPET
A special section entitled Nanotechnology-based
Delivery Strategies for Protein and Peptide
Therapeutics is expected to be published in the January 2024 issue of The Journal of Pharmacology and Experimental Therapeutics.
Protein and peptide therapeutics promise significant clinical advantages in severe disorders such as cancer, diabetes, multiple sclerosis, and autoimmune diseases. Their higher potency, greater specificity, and fewer immunological responses all account for these advantages. However, protein and peptide therapeutics also have delivery challenges due to their low oral bioavailability, low plasma stability, short circulation time in the biological milieu, immunogenicity and inability to cross cell membranes.
This special section is a call for original research as well as authoritative reviews focused on varied nanotechnology-driven delivery approaches for protein and peptide-based therapeutics. Prospective articles can include:
■ Nanocarrier-based delivery strategies ■ PEGylation of protein and peptides ■ Hydrophobization ■ Encapsulation/Electrostatic interaction ■ Self-assembly via electrostatic interactions ■ Hydrogen bonding ■ Hydrophobic interactions ■ Polymerization-based encapsulation ■ Co-delivery with permeation enhancers or protease inhibitors and active targeting by ligand/antibody/peptide conjugation for site-specific delivery
Full-length articles focusing on, but not limited to, the above-mentioned aspects of protein and peptide delivery will be considered. Please send a presubmission inquiry including title, author information, abstract, and significance statement to The Journal of Pharmacology and Experimental Therapeutics prior to full submission.
The guest editors, Prof. Anupama Mittal and Prof. Deepak Chitkara, will review these presubmission inquiries, respond to the authors with comments, and assess whether final approval will be granted for a full submission. All submissions to the journal must refer to the journal’s Instructions to Authors before submission of articles. The full paper submission deadline is March 2023.
Highlighted Trainee Authors
Congratulations to the latest Highlighted Trainee Authors selected for Drug Metabolism and Disposition, The Journal of Pharmacology and Experimental Therapeutics, and Molecular Pharmacology:
Drug Metabolism and Disposition
■ Mengyue (Melody) Yin (Univ. of
Washington) – September ■ Dr. Ziteng Wang (National Univ. of Singapore) – October
JPET
■ Emily Stevenson (Rutgers) –
September ■ Dr. Nikhil Patil (Univ. of Oklahoma
Health Sciences Center) –
October ■ Dr. Gisela Camacho Hernandez (NIDA-IRP) – November
Molecular Pharmacology
■ Dr. Franziska Heydenreich (MRC
Laboratory of Molecular Biology,
Cambridge, UK) – September ■ Dr. Irina Teslenko (Janssen
Research & Development) –
November Mengyue Yin Dr. Ziteng Wang
Emily Stevenson Dr. Nikhil Patil
Dr. Franziska Heydenreich Dr. Irina Teslenko Dr. Gisela Camacho Hernandez
A brief description of their areas of research, current projects, the anticipated impact of their work, and what they enjoy when not in the lab is online at https://bit.ly/2yX1YeH. Congratulations to all for being selected.
